Song QB, Wang Q, Hu WG. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(14): 4365-4372 [PMID: 25892888 DOI: 10.3748/wjg.v21.i14.4365]
Corresponding Author of This Article
Qi-Bin Song, Professor, Department of Oncology, Renmin Hospital of Wuhan University, Zhangzhidong District, Wuhan 430060, Hubei Province, China. qibinsong@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 14, 2015; 21(14): 4365-4372 Published online Apr 14, 2015. doi: 10.3748/wjg.v21.i14.4365
Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis
Qi-Bin Song, Qi Wang, Wei-Guo Hu
Qi-Bin Song, Qi Wang, Wei-Guo Hu, Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
Author contributions: Song QB, Wang Q and Hu WG contributed equally to this work; Song QB designed the research; Wang Q performed the research; Hu WG analyzed the data; Wang Q wrote the paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Qi-Bin Song, Professor, Department of Oncology, Renmin Hospital of Wuhan University, Zhangzhidong District, Wuhan 430060, Hubei Province, China. qibinsong@163.com
Telephone: +86-27-88041911 Fax: +86-27-88041911
Received: July 20, 2014 Peer-review started: July 20, 2014 First decision: August 15, 2014 Revised: September 10, 2014 Accepted: October 15, 2014 Article in press: October 15, 2014 Published online: April 14, 2015 Processing time: 268 Days and 21.9 Hours
Core Tip
Core tip: In this study, we evaluated the correlation between Kirsten rat sarcoma viral oncogene homolog (KRAS) status and the therapeutic effects of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) in patients with metastatic colorectal cancer. We focused on the relationship between KRAS status and the curative effect of anti-EGFR MoAbs in patients with metastatic colorectal cancer, and conducted a systematic meta-analysis of chemotherapy regimens, line of treatment and bevacizumab treatment. This analysis provides the first evidence that patients with wild-type KRAS metastatic colorectal cancer may not benefit from anti-EGFR MoAbs and oxaliplatin-based therapy as first-line treatment. Clinical benefit was confined to therapeutic regimens which included anti-EGFR MoAbs and fluorouracil-based therapy.
